Drug Profile
Edifoligide
Alternative Names: CGT003; CGT021; E2F Decoy; E2F transcription factor decoyLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Brigham and Womens Hospital; Stanford University
- Class Oligonucleotides; Vasodilators
- Mechanism of Action Cdc2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary artery restenosis; Vascular graft occlusion
Most Recent Events
- 28 Mar 2005 Discontinued - Phase-I for Coronary artery restenosis in Japan (unspecified route)
- 28 Mar 2005 Discontinued - Phase-II for Coronary artery restenosis in Germany (unspecified route)
- 28 Mar 2005 Discontinued - Phase-III for Coronary artery restenosis in USA (unspecified route)